Engene reports second quarter 2024 financial results and provides a business update

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, eg-70, is in a pivotal study for bcg-unresponsive high-risk non-muscle invasive bladder cancer (nmibc), today announced its financial results for the second quarter ended april 30, 2024, and provided a business update. “our $200 million private placement in february positioned us well to execute our p.
ENGN Ratings Summary
ENGN Quant Ranking